Table 5. Improvement in marrow blast count, neutrophil count, and platelet count in patients receiving obatoclax.

Patient	Treatment (phase)	AML Classification	Blast count, % (aspirate)		Neutrophils, ×103/µL		Platelets, ×103/µL
			Base-line	End Cycle 2	Baseline	End Cycle 2	Baseline	End Cycle 2
04.002*	20 mg/d (I)	M4	27	10	9344	14,700	227	206
04.003	20 mg/d (I)	M3	27	20	3300	4400	126	139
05.002	20 mg/d (II)	M1	33	23	390	360	49	47

*Received eight cycles of obatoclax.

AML, acute myeloid leukemia.